Insider Buying: Boston Scientific (NYSE:BSX) Director Purchases $99,987.30 in Stock

Boston Scientific Corporation (NYSE:BSX) Director Cheryl Pegus bought 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Boston Scientific Stock Up 1.0%

NYSE:BSX opened at $57.71 on Friday. The firm’s 50-day moving average price is $61.97 and its 200-day moving average price is $80.25. The company has a market capitalization of $85.77 billion, a PE ratio of 24.15, a P/E/G ratio of 1.06 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share buyback program on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its shares are undervalued.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Barclays reduced their target price on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. Bank of America reduced their target price on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Needham & Company LLC reissued a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research report on Monday, May 18th. JPMorgan Chase & Co. cut their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, Robert W. Baird cut their price objective on shares of Boston Scientific from $78.00 to $75.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $92.71.

Institutional Trading of Boston Scientific

A number of institutional investors have recently made changes to their positions in the stock. Groupama Asset Managment boosted its holdings in shares of Boston Scientific by 0.6% during the 1st quarter. Groupama Asset Managment now owns 1,375,261 shares of the medical equipment provider’s stock valued at $86,298,000 after acquiring an additional 8,356 shares during the last quarter. Compass Capital Management Inc. boosted its holdings in shares of Boston Scientific by 21.7% during the 1st quarter. Compass Capital Management Inc. now owns 710,874 shares of the medical equipment provider’s stock valued at $44,607,000 after acquiring an additional 126,806 shares during the last quarter. Essential Partners LLC boosted its holdings in shares of Boston Scientific by 2,209.1% during the 1st quarter. Essential Partners LLC now owns 1,016 shares of the medical equipment provider’s stock valued at $64,000 after acquiring an additional 972 shares during the last quarter. Vestor Capital LLC purchased a new stake in shares of Boston Scientific during the 1st quarter valued at about $450,000. Finally, Edgestream Partners L.P. boosted its holdings in shares of Boston Scientific by 340.7% during the 1st quarter. Edgestream Partners L.P. now owns 85,752 shares of the medical equipment provider’s stock valued at $5,381,000 after acquiring an additional 66,293 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.